Finding ways to protect the heart from chemotherapy damage
Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening
This study is looking for ways to protect the heart from damage caused by the cancer drug doxorubicin, using special lab techniques to find new treatments that can help cancer patients keep their hearts healthy while undergoing chemotherapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10891595 on NIH RePORTER |
What this research studies
This research focuses on addressing heart damage caused by the chemotherapy drug doxorubicin, which is commonly used to treat cancer. By using advanced techniques like human induced pluripotent stem cells (iPSCs) and CRISPR screening, the team aims to identify genes and chemical compounds that can protect heart cells from damage. They will create 3D cardiac microtissues that mimic real heart tissue to test the effectiveness of these potential therapies. The ultimate goal is to develop new treatments that can prevent heart-related side effects in cancer patients receiving doxorubicin.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are being treated with doxorubicin and are at risk of heart damage.
Not a fit: Patients who are not receiving doxorubicin or those without a history of chemotherapy-related heart issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that protect cancer patients' hearts from the harmful effects of chemotherapy.
How similar studies have performed: Other research has shown promise in using CRISPR and stem cell technologies to address similar issues, indicating a potential for success in this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Wu, Joseph C. — Stanford University
- Study coordinator: Wu, Joseph C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.